Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleThe Illustrated Post

[18F]Fluoroestradiol Uptake in Irradiated Lung Parenchyma and Draining Nodes

Audrey A. Rich, Neil K. Taunk, David A. Mankoff, Austin R. Pantel and Sophia R. O’Brien
Journal of Nuclear Medicine June 2024, 65 (6) 990-991; DOI: https://doi.org/10.2967/jnumed.123.266511
Audrey A. Rich
1Division of Nuclear Medicine Imaging and Therapy, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neil K. Taunk
2Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David A. Mankoff
1Division of Nuclear Medicine Imaging and Therapy, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Austin R. Pantel
1Division of Nuclear Medicine Imaging and Therapy, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophia R. O’Brien
1Division of Nuclear Medicine Imaging and Therapy, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

A 34-y-old woman with metastatic estrogen receptor (ER)–positive invasive ductal carcinoma of the left breast and biopsy-proven ER-positive sternal metastasis underwent mastectomy, chemotherapy, and radiation to the chest wall and sternum. [18F]fluoroestradiol (FES) PET/CT 1 mo after radiation (Fig. 1A) demonstrated no abnormal uptake. [18F]FES PET/CT 5 mo after radiation (Fig. 1B), after initiation of the ER-blocking agent tamoxifen, demonstrated new avid opacities anteriorly in the left lung (SUVmax, 7.7), as well as avidity in the hilar nodes (SUVmax, 5.6) and superior mediastinal node (SUVmax, 4.5), findings that were favored to represent the acute postradiation changes that can be seen 1–6 mo after completion of radiation (1). [18F]FDG PET/CT 6.5 mo after radiation (Fig. 1C) demonstrated nearly complete resolution of the lung opacities and no abnormal lung or nodal uptake, consistent with resolving postradiation changes. Acute postradiation lung changes can progress to chronic fibrosis starting around 9 mo after radiation or can resolve, as in our patient (1). At 17 mo after radiation, the patient continued to have no evidence of disease.

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

(A) [18F]FES PET/CT (coronal PET maximum-intensity projection [MIP], sagittal fused PET/CT, axial fused PET/CT, and axial CT) 1 mo after radiation, showing no abnormal findings and physiologic uterine uptake (arrow). (B) [18F]FES PET/CT (coronal PET MIP, sagittal fused PET/CT, axial fused PET/CT, and axial CT) 5 mo after radiation and after tamoxifen, showing new avid left lung opacities (black arrows), avid hilar nodes (solid white arrows), and avid superior mediastinal node (dashed white arrow), findings favored to represent acute postradiation changes. Because of ER blockade, no uterine uptake was seen (dotted-dashed white arrow). (C) [18F]FDG PET/CT (coronal PET MIP, axial fused PET/CT, and axial CT) 6.5 mo after radiation, showing nearly resolved lung opacities (arrows) and no abnormal uptake, consistent with resolving postradiation changes. RT = radiation.

Per appropriate use criteria, [18F]FES is rarely appropriate for measuring response to therapy (2), and ER-blocking drugs interfere with [18F]FES binding to tumor ER (3). This case, however, elucidates an [18F]FES false-positive finding after successful ER blockade evidenced by elimination of physiologic uterine [18F]FES avidity (Figs. 1A and 1B).

A retrospective study reported [18F]FES-avid postradiation pulmonary changes without a clear mechanism and without [18F]FES-avid regional nodes (4). Although the lungs have low-level ER (5) that may play a part in [18F]FES uptake in atelectasis, increased uptake despite ER blockade suggests that [18F]FES-avid postradiation lung changes are not due to ER binding and that associated [18F]FES-avid regional nodes may be due to physiologic drainage of [18F]FES from the lungs. This case provides some insight into the nature of false-positive changes on [18F]FES PET/CT after pulmonary radiation and demonstrates the associated finding of [18F]FES-positive draining nodes.

DISCLOSURE

Sophia O’Brien, Austin Pantel, and David Mankoff are consultants for GE Healthcare. No other potential conflict of interest relevant to this article was reported.

Footnotes

  • Published online Jan. 18, 2024.

  • © 2024 by the Society of Nuclear Medicine and Molecular Imaging.

REFERENCES

  1. 1.↵
    1. Benveniste MF,
    2. Gomez D,
    3. Carter BW,
    4. et al
    . Recognizing radiation therapy-related complications in the chest. Radiographics. 2019;39:344–366.
    OpenUrl
  2. 2.↵
    1. Ulaner GA,
    2. Mankoff DA,
    3. Clark AS,
    4. et al
    . Summary: appropriate use criteria for estrogen receptor-targeted PET imaging with 16α-18F-fluoro-17β-fluoroestradiol. J Nucl Med. 2023;64:351–354.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. O’Brien SR,
    2. Edmonds CE,
    3. Lanzo SM,
    4. Weeks JK,
    5. Mankoff DA,
    6. Pantel AR
    . 18F-fluoroestradiol: current applications and future directions. Radiographics. 2023;43:e220143.
    OpenUrl
  4. 4.↵
    1. Venema CM,
    2. de Vries EF,
    3. van der Veen SJ,
    4. et al
    . Enhanced pulmonary uptake on 18F-FES-PET/CT scans after irradiation of the thoracic area: related to fibrosis? EJNMMI Res. 2019;9:82.
    OpenUrl
  5. 5.↵
    1. Mollerup S,
    2. Jorgensen K,
    3. Berge G,
    4. Haugen A
    . Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer. 2002;37:153–159.
    OpenUrlCrossRefPubMed
  • Received for publication August 10, 2023.
  • Revision received December 19, 2023.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 65 (6)
Journal of Nuclear Medicine
Vol. 65, Issue 6
June 1, 2024
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
[18F]Fluoroestradiol Uptake in Irradiated Lung Parenchyma and Draining Nodes
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
[18F]Fluoroestradiol Uptake in Irradiated Lung Parenchyma and Draining Nodes
Audrey A. Rich, Neil K. Taunk, David A. Mankoff, Austin R. Pantel, Sophia R. O’Brien
Journal of Nuclear Medicine Jun 2024, 65 (6) 990-991; DOI: 10.2967/jnumed.123.266511

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
[18F]Fluoroestradiol Uptake in Irradiated Lung Parenchyma and Draining Nodes
Audrey A. Rich, Neil K. Taunk, David A. Mankoff, Austin R. Pantel, Sophia R. O’Brien
Journal of Nuclear Medicine Jun 2024, 65 (6) 990-991; DOI: 10.2967/jnumed.123.266511
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Safety and Efficacy of 20 Cycles of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
  • Uncommon Anomalous Biodistribution of 18F-DCFPyL Prostate-Specific Membrane Antigen: A Case Series
  • [68Ga]Ga-FAPI PET/CT Monitors Response to Receptor Activator of Nuclear Factor-κB Ligand Inhibitor in a Giant Cell Tumor of Bone: Correlation with Histopathology
Show more The Illustrated Post

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire